Concentra Group Holdings Parent reported Q3 2025 revenue of $572.8 million, a 17% increase year-over-year, or $541.5 million (up 10.6%) excluding the Nova acquisition.
Adjusted EBITDA reached $118.9 million, a 17.1% increase from the prior year, with the adjusted EBITDA margin slightly improving to 20.8% in Q3 2025.
The company reported adjusted net income of $49.9 million and adjusted earnings per share of $0.39 for the third quarter of 2025.
Concentra updated its 2025 revenue guidance to a low end of $2.145 billion and adjusted EBITDA guidance to a low end of $425 million, while reaffirming leverage targets of 3.5x or below by year-end 2025 and below 3.0x by year-end 2026.
The Board declared a cash dividend of $0.0625 per share and authorized a $100 million share repurchase program.

Nov 7, 2025, 2:00 PM

Transcript

Concentra Reports Strong Q3 2025 Results and Raises Full-Year Guidance

CON

Earnings

Guidance Update

Share Buyback

Concentra reported strong Q3 2025 financial results, with Total Revenue increasing 17.0% year-over-year to $572.8 million and Adjusted EBITDA growing 17.1% year-over-year to $118.9 million.
The company raised its FY 2025 guidance for Total Revenue to between $2.145 billion and $2.160 billion and for Adjusted EBITDA to between $425 million and $430 million.
Concentra continued its focus on de-leveraging, reducing net leverage to 3.6x in Q3 2025, and authorized a $100 million share repurchase program while maintaining a $0.0625 quarterly dividend.
Operational growth was driven by the integration of Nova and Pivot Onsite acquisitions, along with opening 1 de novo in Q3 2025, targeting 7 total for the year.

Nov 7, 2025, 2:00 PM

Presentation

Concentra Group Holdings Parent, Inc. Announces Q3 2025 Results, Cash Dividend, and Raised FY 2025 Guidance

CON

Earnings

Guidance Update

Dividends

Concentra Group Holdings Parent, Inc. reported strong Q3 2025 financial results, with revenue increasing 17.0% to $572.8 million and Adjusted EBITDA growing 17.1% to $118.9 million compared to Q3 2024.
The company's net income for Q3 2025 was $49.8 million, resulting in earnings per share of $0.38.
Concentra raised its full-year 2025 guidance, now projecting revenue in the range of $2.145 billion to $2.160 billion and Adjusted EBITDA between $425 million and $430 million.
Operational performance was robust, with patient visits per day increasing 9.2% and revenue per visit up 4.2% in Q3 2025 year-over-year.
The Board of Directors declared a quarterly cash dividend of $0.0625 per share and authorized a $100 million share repurchase program.

Nov 6, 2025, 9:40 PM

8-K

Concentra Announces Strong Q2 2025 Results and Raises Full-Year Guidance

CON

Earnings

Guidance Update

M&A

Concentra reported strong Q2 2025 financial performance with Total Revenue of $550.8 million, representing a 15.2% growth year-over-year, and Adjusted EBITDA of $115.0 million, a 13.2% growth year-over-year.
The company raised its full-year 2025 guidance, now expecting Total Revenue between $2.13 billion and $2.16 billion and Adjusted EBITDA between $420 million and $430 million.
Concentra completed the acquisition of Pivot Onsite Innovations on June 1, adding 240+ onsite health clinics and bringing the total number of center and onsite locations to over 1,000 as of June 30, 2025.
The company's net leverage was lowered to 3.8x in Q2 2025, with a focus on de-levering to ~3.5x by year-end 2025 and targeting <3.0x by the end of 2026.

Aug 8, 2025, 1:00 PM

Presentation

Concentra Group Holdings Parent, Inc. Announces Q2 2025 Results, Raises Guidance, and Declares Dividend

CON

Earnings

Guidance Update

M&A

Concentra Group Holdings Parent, Inc. reported Q2 2025 revenue of $550.8 million, an increase of 15.2% from Q2 2024, and Adjusted EBITDA of $115.0 million, up 13.2%. Net income for the quarter was $46.2 million, a decrease from the prior year, primarily due to higher interest expense.
The company raised its full-year 2025 guidance, with expected revenue now between $2.13 billion and $2.16 billion and Adjusted EBITDA in the range of $420 million to $430 million.
Concentra completed the acquisition of Pivot Onsite Innovations on June 1, 2025, for $54.4 million, expanding its network to over 1,000 total locations including 406 onsite health clinics.
A cash dividend of $0.0625 per share was declared on August 6, 2025, payable on August 28, 2025.

Aug 7, 2025, 12:00 AM

8-K

Concentra Closes Acquisition of Pivot Onsite Innovations

CON

M&A

Acquisition Completed: Concentra Group Holdings Parent, Inc. finalized the acquisition of Pivot Onsite Innovations for $55 million, financed with cash on hand and available borrowing capacity.
Strategic Expansion: The deal doubles the size of Concentra’s Onsite Health segment, expanding its network to approximately 350 clinics across over 40 states.

Jun 2, 2025, 12:00 AM

8-K

Concentra Releases Q1 2025 Results

CON

Earnings

Guidance Update

M&A

Robust Q1 performance with revenue up 7.1% YoY and Adj. EBITDA increased by 6.8% YoY, driven by strategic acquisitions (Nova, PHC) and de novo openings.
FY 2025 guidance raised to $2.1bn–$2.15bn in revenue and $415mm–$430mm in Adj. EBITDA, with a maintained quarterly dividend of $0.0625 per share.
Ongoing focus on de-leveraging with targets of approximately 3.5x net leverage by year-end and 3.0x in the next 18–24 months.

May 8, 2025, 1:00 PM

Presentation

Concentra Announces Acquisition Agreement for Pivot Onsite Innovations

CON

M&A

Concentra Group Holdings Parent, Inc. signed a definitive agreement to acquire Pivot Onsite Innovations as part of its strategic expansion in the occupational health space.
The acquisition will bring a network of over 200 onsite health clinics across more than 40 states, effectively doubling the size of Concentra’s growing Onsite Health operating segment.
The transaction is valued at approximately $55 million and is expected to close in the second quarter of 2025, with funding to be sourced from cash on hand and available borrowing capacity.

Apr 21, 2025, 12:00 AM

8-K

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for CON.

No recent filings or transcripts found for CON.